AUTHORS
Jieya Wu, MD, Guangrong Qin, PhD2, Brian John Ball, MD, MS3, Michelle Afkhami4, Diana Knobler5, Marjorie Robbins, PhD6, Khyati Joshi7, Yueming Tang, MD,PhD8, Lucy Ghoda, PhD9, Jacob S Appelbaum, Md, PhD10, Sergei Doulatov, PhD11, Stanley Lee, PhD12, Timothy Martins, PhD13, Holly Yin, PhD14, Tim Monahan15, Derek Stirewalt, MD16, Marie Bleakley Jr, PhD, MBBS, MMSc17, Guido Marcucci, MD18, Pamela S. Becker, MD, PhD19
AFFILIATIONS
1 City of Hope, Duarte, California, United States
2 Institute for Systems Biology, Seattle, United States
3 City of Hope, Duarte, California, United States
4 City of Hope, Duarte, California, United States
5 City of Hope, Duarte, California, United States
6 City of Hope, Duarte, California, United States
7 City of Hope, Duarte, California, United States
8 City of Hope, Duarte, California, United States
9 City of Hope, Duarte, California, United States
10 University of Washington, Seattle, United States
11 Columbia University, New York, United States
12 Fred Hutchinson Cancer Center, Seattle, United States
13 University of Washington, Seattle, United States
14 City of Hope, Duarte, California, United States
15 Fred Hutchinson Cancer Center, Seattle, United States
16 Fred Hutchinson Cancer Center, Seattle, United States
17 Fred Hutchinson Cancer Center, Seattle, United States
18 City of Hope, Duarte, California, United States
19 City of Hope, Duarte, California, United States
ABSTRACT
Background
Transformation of myelodysplastic neoplasms (MDS) to secondary acute myeloid leukemia (sAML) is associated with poor survival and remains a major cause of disease-related mortality. Although molecular profiling has substantially improved prognostic risk stratification, predicting when individual patients will undergo leukemic transformation and identifying effective therapeutic opportunities before progression remain major clinical challenges. Clonal evolution through sequential acquisition of somatic mutations leading to proliferative advantage and treatment resistance is a key driver of disease progression. Recently, Civettini et al. (NEJM Evidence 2026) developed the IPSS-M-Evo model, demonstrating that recurrent clonal evolutionary trajectories provide prognostic information beyond the molecular risk assigned by IPSS-M. These findings suggest that understanding evolutionary trajectories may not only improve prognosis but also identify therapeutically actionable vulnerabilities.
Objectives
To characterize longitudinal clonal evolution during progression from MDS to sAML, evaluate concordance with IPSS-M-Evo evolutionary trajectories, and determine whether functional drug sensitivity profiling identifies therapeutic vulnerabilities associated with high-risk disease evolution and leukemic transformation.
Methods
Longitudinal genomic profiling of serial samples from 24 patients with MDS or related myeloid neoplasms was obtained through City of Hope's POSEIDON database and analyzed to reconstruct patient-specific evolutionary trajectories for comparison with those predicted by the IPSS-M-Evo model. In separate studies, patient-derived mononuclear cells from MDS and sAML marrow and blood samples underwent multiparameter flow cytometry-based high-throughput drug screening using the iQue3 platform and a custom 64-drug panel. Drug Sensitivity Scores (DSS) were calculated from gated blast-cell viability following 72-hour drug exposure using Breeze 2.0. Twenty-seven samples were evaluable, including MDS with low blasts (MDS-LB, n=2), MDS with increased blasts 1 (MDS-IB1, n=5), MDS with increased blasts 2 (MDS-IB2, n=13), and sAML (n=7). Two-sided Mann-Whitney U tests were performed for each agent to compare disease stage and cytogenetic subgroups.
Results
Longitudinal genomic profiling demonstrated progressive acquisition of progression-associated mutations involving the RAS pathway, FLT3, RUNX1, SETBP1, and other myeloid driver genes, together with increasing mutational complexity during disease evolution. Representative patients demonstrated sequential acquisition of cooperating mutations, including DNMT3A→NF1, progressive RUNX1 diversification with acquisition of IDH1, KMT2D, and NRAS, and acquisition of BCOR and RUNX1 downstream of DNMT3A/SF3B1, consistent with recurrent IPSS-M-Evo trajectories. A subset of predicted downstream mutations was observed in longitudinal samples. Most patients demonstrated partial concordance with IPSS-M-Evo predictions, acquiring one or more expected downstream mutations without fully recapitulating complete evolutionary trajectories, suggesting that patient-specific mutation combinations may further refine trajectory-based risk prediction and therapeutic stratification.
Functional drug sensitivity profiling demonstrated substantial inter-patient heterogeneity across the 64-drug panel, with hierarchical clustering showing overlapping response patterns between MDS and sAML samples. No differential drug sensitivities were identified between MDS-LB plus MDS-IB1 and MDS-IB2. In contrast, sAML showed greater sensitivity to roxadustat (P=0.018), fedratinib (P=0.034), and IRAK4-IN-7 (P=0.047), suggesting acquisition of therapeutic vulnerabilities during leukemic transformation. Exploratory subgroup analyses identified increased sensitivity in complex cytogenetics to tasquinimod, trametinib, fedratinib, and momelotinib (all P<0.05), while standard-risk (good/intermediate-risk) MDS demonstrated increased sensitivity to vorinostat, abemaciclib, sorafenib, ponatinib, daunorubicin, panobinostat, selinexor, and SX-682 compared with high-risk (poor/very poor-risk) MDS (all P<0.05).
Conclusion
Integrating high-risk mutational trajectories and predicted clonal evolution with functional drug sensitivity profiling may improve personalized therapeutic strategies for patients with MDS, refine risk-adapted intervention, and support identification of therapeutic vulnerabilities before AML transformation.
DISCLOSURES
Jieya Wu, MD: No relevant conflicts of interest to declare.